Search - tctmd.com

Displaying 61 - 80 of 280

Sort: Relevancy | Date

News Daily News

Women, Minorities at Greater Risk for Non-Stent-Related Events After PCI

Yael L. Maxwell

October 20, 2017

News Daily News

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Michael O'Riordan

October 17, 2017

News Daily News

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Michael O'Riordan

October 11, 2017

Presentation ESC 2017

BIOFLOW V Comparison of Ultrathin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus-Eluting Durable Polymer Stents

Presenter: David E Kandzari

September 13, 2017

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

News Daily News

Boston Scientific Scraps Biodegradable Scaffold Program

Michael O'Riordan

August 01, 2017

News Industry News

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

July 25, 2017

News Features EuroPCR 2017

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

Yael L. Maxwell

June 01, 2017

News Conference News EuroPCR 2017

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

Michael O'Riordan

May 19, 2017

News Conference News EuroPCR 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Michael O'Riordan

May 18, 2017

Presentation EuroPCR 2017

Randomized Comparison of Everolimus-eluting Bioresorbable Vascular Scaffolds vs. Everolimus-eluting Metallic Stents in Patients with Coronary Artery Disease: 3-year Clinical Outcomes from ABSORB China

Presenter: Runlin Gao

May 17, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News EuroPCR 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Michael O'Riordan

May 15, 2017

News Conference News SCAI 2017

Bioresorbable Scaffolds: Where Do We Go From Here?

L.A. McKeown

May 15, 2017

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

Presentation

Economic Outcomes of Absorb BVSvs Everolimus-Eluting Stents in PCI

April 18, 2017

News Opinion Fellow Talk

The Left Main Debate: What Does it Mean for the Future of Intervention?

Tiffany Patterson, MBBS

April 12, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

Advertisement

Women, Minorities at Greater Risk for Non-Stent-Related Events After PCI

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

BIOFLOW V Comparison of Ultrathin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus-Eluting Durable Polymer Stents

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Boston Scientific Scraps Biodegradable Scaffold Program

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Randomized Comparison of Everolimus-eluting Bioresorbable Vascular Scaffolds vs. Everolimus-eluting Metallic Stents in Patients with Coronary Artery Disease: 3-year Clinical Outcomes from ABSORB China

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Bioresorbable Scaffolds: Where Do We Go From Here?

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Economic Outcomes of Absorb BVSvs Everolimus-Eluting Stents in PCI

The Left Main Debate: What Does it Mean for the Future of Intervention?

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content